Phase I study of the oral vascular endothelial growth factor inhibitor PTK787/ZK 222584 [vatalanib] in combination with paclitaxel in patients with advanced solid tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Nov 2009
At a glance
- Drugs Paclitaxel; Vatalanib
- Indications Solid tumours
- Focus Adverse reactions
- 03 Nov 2009 Planned end date changed from 1 Apr 2008 to 1 Apr 2010 as reported by ClinicalTrials.gov.
- 06 Jan 2009 Status changed from recruiting to active, no longer recruiting, as reported on ClinicalTrials.gov.
- 03 Nov 2006 New trial record.